A UK vision for life science SMEs - but will it cut the mustard with government?
This article was originally published in Clinica
The voice of life science companies was echoing around the UK last month in response to a call from the industry to tell the government what they need to help them succeed.
You may also be interested in...
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.